Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant.

Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant.
复制标题

DOI:
10.1016/j.ebiom.2015.03.016
复制
发表时间:
2015-05-01
期刊:
影响因子:
11.1
通讯作者:
Zhang, Yuesheng
Zhang, Yuesheng
中科院分区:
医学1区
文献类型:
--
作者:
Yang, Lu;Li, Yun;Bhattacharya, Arup;Zhang, Yuesheng

文献摘要

参考文献

被引文献

相似文献

ERBB2 is an oncogenic receptor tyrosine kinase overexpressed in a subset of human breast cancer and other cancers. We recently found that human prolidase (PEPD), a dipeptidase, is a high affinity ERBB2 ligand and cross-links two ERBB2 monomers. Here, we show that recombinant human PEPD (rhPEPD) strongly inhibits ERBB2-overexpressing tumors in mice, whereas it does not impact tumors without ERBB2 overexpression. rhPEPD causes ERBB2 depletion, disrupts oncogenic signaling orchestrated by ERBB2 homodimers and heterodimers, and induces apoptosis. The impact of enzymatically-inactive mutant rhPEPDG278D on ERBB2 is indistinguishable from that of rhPEPD, but rhPEPDG278D is superior to rhPEPD for tumor inhibition. The enzymatic function of rhPEPD stimulates HIF-1α and other pro-survival factors in tumors, which likely attenuates its antitumor activity. rhPEPDG278D is also attractive in that it may not interfere with the physiologic function of endogenous PEPD in normal cells. Collectively, we have identified a human protein as an inhibitory ERBB2 ligand that inhibits ERBB2-overexpressing tumors in vivo. Several anti-ERBB2 agents are on the market but are hampered by drug resistance and high drug cost. rhPEPDG278D may synergize with these agents and may also be highly cost-effective, since it targets ERBB2 with a different mechanism and can be produced in bacteria. Human prolidase (rhPEPD) inhibits the growth of ErbB2-overexpressing tumors. rhPEPD disrupts the signaling complexes assembled by ErbB2 homo- and hetero-dimers. Enzymatically-inactive rhPEPDG278D is superior to rhPEPD for tumor inhibition.
DOI: 10.1016/j.ccr.2009.03.020
发表时间: 2009-05-05
期刊: CANCER CELL
影响因子: 50.3
作者:
Junttila, Teemu T.;Akita, Robert W.;Sliwkowski, Mark X.
通讯作者: Sliwkowski, Mark X.
DOI: 10.1038/nature01392
发表时间: 2003-02-13
期刊: NATURE
影响因子: 64.8
作者:
Cho, HS;Mason, K;Leahy, DJ
通讯作者: Leahy, DJ
DOI: 10.1111/j.1365-2613.2006.00486.x
发表时间: 2006-08-01
影响因子: 3
作者:
Cechowska-Pasko, Marzanna;Palka, Jerzy;Wojtukiewicz, Marek Z.
通讯作者: Wojtukiewicz, Marek Z.
DOI: 10.1371/journal.pbio.1000563
发表时间: 2010-12-21
期刊: PLoS biology
影响因子: 9.8
作者:
Gijsen M;King P;Perera T;Parker PJ;Harris AL;Larijani B;Kong A
通讯作者: Kong A
DOI: 10.1158/1078-0432.ccr-14-0012
发表时间: 2014-09-01
影响因子: 11.5
作者:
Amiri-Kordestani, Laleh;Blumenthal, Gideon M.;Cortazar, Patricia
通讯作者: Cortazar, Patricia